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The prevalence of atrial fibrillation (AF) in the entire US population is approximately 1%. 1 The prevalence of AF increases substantially with age, with up to 9% of patients over the age of 80 developing AF. The population presenting with permanent pacing requirements also increases with age and the cumulative lifetime risk of developing paroxysmal AF in pacemaker patients may be as high as 40%.
Mechanisms for AF initiation and maintenance are multiple, but are widely accepted to be a result of triggered initiation, by atrial premature beats (APB), and maintenance within the atrial substrate based on multiple wavelets of reentry and rotors that depend on inhomogeneous atrial refractory periods (ARP) and atrial conduction velocities (ACV). Atrial pacing may prevent both AF triggers and atrial substrate changes by suppressing APB and inducing a more homogenous atrial landscape of refractory periods and conduction velocities. Atrial based pacing is clearly superior to ventricular pacing alone in preventing atrial fibrillation with an 18% relative risk reduction with atrial based pacing over a 3 year follow up. 3 This treatment effect has been postulated to be the result of APB suppression and changes in ARP and ACV as a result of atrial stretch due to higher atrial pressure from AV dyssynchronous pacing. The atrial changes associated with atrial based pacing could possibly be enhanced by atrial overdrive pacing algorithms and/or by alternative site atrial pacing such as the atrial septum. The role of alternative site atrial pacing in the primary prevention of AF in pacemaker patients and the progression of AF (secondary prevention) is also not well established. In addition, despite the initial enthusiasm for overdrive atrial pacing algorithms, the recent ASSERT trial did not demonstrate any efficacy with overdrive atrial pacing in the primary prevention of AF. 4 Tse et al present a randomized trial comparing both sites of atrial pacing and the effects of atrial overdrive pacing algorithms in the prevention of persistent atrial fibrillation in patients prevent both AF triggers and atrial substrate changes by suppressing APB and ind nd duc uc cin in ng g g a a a mo mo more re homogenous atrial landscape of refractory periods and conduction velocities. Atrial based pacing s s c cle le lear ar arl ly ly s s sup up u e erio o or r r to to ventricular pacing alone in n pr p p e e eventing atrial l f f fibri ill ll llat at atio i n with an 18% e ela a ati tive risk re edu du duct t tio on n n wi wi with th th a a atr tr tri ia ial l ba ba base sed d p p paci ing ng g ov ver r r a 3 3 3 y ye yea a ar f fol oll lo ow w w up up. . with sick sinus syndrome (SSS) and paroxysmal AF. 5 The investigators randomized 385 patients with known AF and SSS to right atrial (RA) septum pacing and RA appendage (RAA) pacing. In addition, patients were randomized at both sites to an atrial overdrive pacing algorithm ON mode or just standard demand atrial based pacing. The primary endpoint was a "secondary prevention"
endpoint of AF progression (in this patient population with known AF) to persistent AF defined as AF lasting for 7 days or the need for a cardioversion. In addition, the number of atrial high rate episodes (AHRE) lasting >6 minutes were compared across the randomized groups.
Importantly, there was no cross-overs in the overdrive pacing ON and OFF groups and only 1% (4 patients total) did not have an atrial lead implanted in the randomized location.
The main findings of the study are that persistent AF-free survival was not statistically different between RA septal pacing and RAA and between overdrive atrial pacing algorithm ON and OFF. The progression to persistent AF amongst the 4 randomized groups was, with a mean annual rate of of f p p per er e si si sist st s en en ent t t AF AF F w w was as sui ui ite t t h h hig ig igh h h at at at 8. 8. 8 3% 3% 3%. . In In a a add dd ddit it itio io ion, n, n, t the he e n n num um umbe be ber r r of of of A A AHR HR HRE E lasting >6 6 6 2. Minimizing right ventricular pacing will decrease the risk of AF in patients with sinus node dysfunction. 6 3. There are no compelling trial data at this time, including data from the SAFE trial, to support alternative single-site RA pacing over standard RAA pacing for either the primary prevention of AF or secondary prevention of persistent AF.
4. There are no compelling trial data at this time, including data from the SAFE trial, to support overdrive atrial pacing algorithms for the primary prevention of AF or secondary prevention of persistent AF.
5. Although overdrive atrial pacing algorithms are successful in increasing the percentage of atrial pacing, the lack of benefit in the primary prevention of AF and secondary prevention of persistent AF make the "cost" in terms of battery life unfavorable.
1. Atrial pacing is superior to ventricular pacing in primary prevention of AF AF F i in n n pa pa pati ti ien en ents ts t with sinus node dysfunction or AV block. Patients in sinus rhythm requiring a pacemaker f fo for r r br br bra adyc yc yca ar ardia should receive a device c c cap ap a a able of atrial p p pac a a in ng. g. g 2 2. Minimi mizi zi zing g g r rig ig ight ht t v ven en entr tr tric icul ul lar ar r p pac aci ing w will d d dec creas as ase e th th he e ri risk sk o of f A AF AF i in n pa pa pat ti tien ent ts t w w wit it ith si si sinu nu us s no node de de d d dys ys sfu fu unc nct ti ion n n. 9. There continues to be no role for permanent pacing, in the absence of a bradycardia indication, to prevent AF.
Based on current clinical knowledge, for patients with bradycardia, PAF, and sinus rhythm, atrial based pacing with an RA lead placed in a stable position with good electrical performance, minimization of unnecessary RV pacing, and careful consideration of anticoagulation are far more important than placement of the atrial lead at any specific location for single-site RA pacing and any currently available overdrive atrial pacing algorithm.
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8. Other forms of atrial pacing such as multi-site RA pacing or biatrial pacing for primary pr prev ev even en ntion on on o of AF or the secondary preven en ent tio o on of progress sio io i n to to o p p pe ersistent AF need further r cl cl clin n nic cal al a i inv nv nve es esti ti tig ga gati tion on on be be efo fo ore w w wi i ide s sp spr read ad d a ado do op pt tio ion n n.
9. 9. Th Ther er ere e e co con nt ntin in i ue ue es to to be e e no no o r r rol ol ole e fo fo for r r pe pe perm rm rman an ane en ent t t pa pa aci ci ing ng ng, , , in n n t th h he a a abs bs b e e enc ce ce o o of f a a a br br rad ad adyc yca ar ard di dia a indica cati ti tion on o , , to to o p p pre re eve e ent nt nt A AF. F. F by guest on November 11, 2017
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